Spero Therapeutics Inc (SPRO)
1.63
-0.06
(-3.55%)
USD |
NASDAQ |
May 10, 16:00
1.63
0.00 (0.00%)
After-Hours: 19:01
Spero Therapeutics Enterprise Value: 14.75M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 14.75M |
| May 08, 2024 | 13.67M |
| May 07, 2024 | 13.13M |
| May 06, 2024 | 13.13M |
| May 03, 2024 | 11.51M |
| May 02, 2024 | 10.43M |
| May 01, 2024 | 6.932M |
| April 30, 2024 | 0.1949M |
| April 29, 2024 | 1.273M |
| April 26, 2024 | 2.351M |
| April 25, 2024 | 0.7338M |
| April 24, 2024 | 0.1949M |
| April 23, 2024 | 1.003M |
| April 22, 2024 | -0.6135M |
| April 19, 2024 | -0.8829M |
| April 18, 2024 | 2.890M |
| April 17, 2024 | 4.506M |
| April 16, 2024 | 2.890M |
| April 15, 2024 | 6.123M |
| April 12, 2024 | 12.05M |
| April 11, 2024 | 15.82M |
| April 10, 2024 | 15.28M |
| April 09, 2024 | 14.75M |
| April 08, 2024 | 14.21M |
| April 05, 2024 | 12.59M |
| Date | Value |
|---|---|
| April 04, 2024 | 14.71M |
| April 03, 2024 | 20.09M |
| April 02, 2024 | 20.63M |
| April 01, 2024 | 20.09M |
| March 28, 2024 | 16.32M |
| March 27, 2024 | 17.94M |
| March 26, 2024 | 16.86M |
| March 25, 2024 | 14.71M |
| March 22, 2024 | 17.94M |
| March 21, 2024 | 16.86M |
| March 20, 2024 | 18.48M |
| March 19, 2024 | 19.55M |
| March 18, 2024 | 16.86M |
| March 15, 2024 | 20.09M |
| March 14, 2024 | 17.40M |
| March 13, 2024 | 13.09M |
| March 12, 2024 | 13.09M |
| March 11, 2024 | 17.40M |
| March 08, 2024 | 13.09M |
| March 07, 2024 | 15.36M |
| March 06, 2024 | 14.83M |
| March 05, 2024 | 12.18M |
| March 04, 2024 | 12.18M |
| March 01, 2024 | 13.24M |
| February 29, 2024 | 11.12M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-96.64M
Minimum
Jun 28 2022
527.97M
Maximum
Sep 23 2021
130.08M
Average
96.84M
Median
Mar 10 2020
Enterprise Value Benchmarks
| Anika Therapeutics Inc | 301.70M |
| OptiNose Inc | 185.41M |
| scPharmaceuticals Inc | 136.22M |
| electroCore Inc | 31.47M |
| NovaBay Pharmaceuticals Inc | 2.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 51.19M |
| Revenue (Quarterly) | 71.82M |
| Total Expenses (Quarterly) | 21.29M |
| EPS Diluted (Quarterly) | 0.97 |
| Profit Margin (Quarterly) | 71.27% |
| Earnings Yield | 26.38% |
| Operating Earnings Yield | 31.01% |
| Normalized Earnings Yield | 31.26 |